Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.2.2
Commitments and Contingencies (Details Narrative)
€ in Millions
 1 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2021
USD ($)
Jul. 31, 2012
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2022
EUR (€)
Sep. 30, 2021
USD ($)
Loss Contingencies [Line Items]              
Annual license fee         $ 200,000    
Payment for annual license fee obligation         100,000 € 0.1  
Payment to acquire in process research and development         896,477  
Discovery Collaboration Agreements [Member] | XOMA [Member]              
Loss Contingencies [Line Items]              
Milestone payments       $ 3,800,000      
Annual license fee         $ 500,000    
Cellca Agreement [Member]              
Loss Contingencies [Line Items]              
Description of milestone payments         The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised. The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.  
The Cellca Agreement [Member]              
Loss Contingencies [Line Items]              
Milestone payments         $ 600,000    
The Cellca Agreement [Member] | In Process Research and Development [Member]              
Loss Contingencies [Line Items]              
Annual license fee         100,000    
The Cellca Agreement [Member] | Minimum [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation         100,000    
The Cellca Agreement [Member] | Maximum [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation         600,000    
The Brink Agreement [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation     $ 100,000        
Commerical product license fee payment obligation     $ 100,000        
The InvivoGen Agreement [Member] | In Process Research and Development [Member]              
Loss Contingencies [Line Items]              
Annual license fee $ 24,600       100,000    
The ProteoNic Agreement [Member]              
Loss Contingencies [Line Items]              
Contingent milestone payments         1,200,000 € 1.2  
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]              
Loss Contingencies [Line Items]              
Milestone payments   $ 1,000,000.0          
Payment to acquire in process research and development         $ 100,000